CD73

Assets acting on this target.

Class
CD73 inhibitor
Pathway
Blocks CD73-mediated extracellular adenosine production, reversing adenosine-driven immunosuppression

CD73 is an enzyme anchored to the outer surface of cells that converts extracellular AMP, a breakdown product of ATP, into adenosine. In healthy tissue this reaction helps limit excessive inflammation, but tumors frequently exploit the same pathway: dying and stressed cells release large amounts of ATP, and enzymes including CD73 convert it into adenosine within the tumor microenvironment. Adenosine then engages receptors on T cells and other immune cells, dampening their ability to recognize and destroy tumor cells. By blocking CD73's enzymatic activity, antibodies targeting this protein reduce local adenosine production and aim to restore antitumor immune activity, particularly in cancers where the tumor microenvironment is immunosuppressive or where response to other immune-directed therapies has been limited by this pathway. Because CD73 acts on an extracellular substrate, it is accessible to large-molecule antibodies as well as small-molecule enzyme inhibitors, allowing different modalities to achieve the same functional block. This mechanism sits within the broader purinergic signaling pathway that regulates immune tone, tissue repair, and vascular function, so modulating it can carry effects beyond the tumor itself.

By indication

Related mechanisms

CD73 drugs compared

5 drugs, stage by indication
5 drugs acting on CD73: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
OleclumabMedImmune LLCmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
UliledlimabNovaBridge Biosciences, TJ Biopharma Co., Ltd.monoclonal antibodyPhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer
MavrostobartPhanes Therapeuticsmonoclonal antibodyPhase 1/2Not recorded
MupadolimabAngel Pharmaceuticals, Corvus Pharmaceuticalsmonoclonal antibodyPhase 1Phase 1 in Non-Small Cell Lung Cancer
ORIC-533ORIC Pharmaceuticalssmall moleculePhase 1Phase 1 in Multiple Myeloma

← all mechanisms